EGCG-Derivative G28 Shows High Efficacy Inhibiting the Mammosphere-Forming Capacity of Sensitive and Resistant TNBC Models

JAK/STAT3-Regulated Fatty Acid β-Oxidation Is Critical for Breast Cancer Stem Cell Self-Renewal and Chemoresistance

(2018) Tianyi Wang et al.   Cell Metabolism

A review of the value of human epidermal growth factor receptor 2 (HER2)-targeted therapies in breast cancer

(2018) N.A. Nixon et al.   EUROPEAN JOURNAL OF CANCER

(−)-Epigallocatechin 3-Gallate Synthetic Analogues Inhibit Fatty Acid Synthase and Show Anticancer Activity in Triple Negative Breast Cancer

(2018) Joan Crous-Masó et al.   MOLECULES

Targeting Breast Cancer Stem Cells to Overcome Treatment Resistance

(2018) Sònia Palomeras et al.   MOLECULES

Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods

(2018) J. Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER

Human cancer stem cells are a target for cancer prevention using (−)-epigallocatechin gallate

(2017) Hirota Fujiki et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Fatty acid synthase expression and its association with clinico-histopathological features in triple-negative breast cancer

(2017) Ariadna Giró-Perafita et al.   Oncotarget

Preclinical Evaluation of Fatty Acid Synthase and EGFR Inhibition in Triple-Negative Breast Cancer

(2016) A. Giro-Perafita et al.   CLINICAL CANCER RESEARCH

Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease

(2016) Giampaolo Bianchini et al.   Nature Reviews Clinical Oncology

Suppression of endogenous lipogenesis induces reversion of the malignant phenotype and normalized differentiation in breast cancer

(2016) Anatilde M. Gonzalez-Guerrico et al.   Oncotarget

Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway

(2016) Daniela Massihnia et al.   Oncotarget

Warburg Effect - a Consequence or the Cause of Carcinogenesis?

(2016) Slobodan Devic   Journal of Cancer

Inhibition of Fatty Acid Synthase Decreases Expression of Stemness Markers in Glioma Stem Cells

(2016) Yuki Yasumoto et al.   PLoS One

Fatty acid synthase overexpression: target for therapy and reversal of chemoresistance in ovarian cancer

(2015) Dirk O Bauerschlag et al.   Journal of Translational Medicine

Regulation of stem cells-related signaling pathways in response to doxorubicin treatment in Hs578T triple-negative breast cancer cells

(2015) Oana Tudoran et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

Distinct EMT programs control normal mammary stem cells and tumour-initiating cells

(2015) Xin Ye et al.   NATURE

Dual Fatty Acid Synthase and HER2 Signaling Blockade Shows Marked Antitumor Activity against Breast Cancer Models Resistant to Anti-HER2 Drugs

(2015) Adriana Blancafort et al.   PLoS One

Increased expression of fatty acid synthase provides a survival advantage to colorectal cancer cells via upregulation of cellular respiration

(2015) Yekaterina Y. Zaytseva et al.   Oncotarget

Breast cancer stem cells, EMT and therapeutic targets

(2014) Srishti Kotiyal et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Current status of hormone therapy in patients with hormone receptor positive (HR+) advanced breast cancer

(2014) Elsa Dalmau et al.   BREAST

Transient SNAIL1 Expression Is Necessary for Metastatic Competence in Breast Cancer

(2014) H. D. Tran et al.   CANCER RESEARCH

Fatty acid synthase is a metabolic marker of cell proliferation rather than malignancy in ovarian cancer and its precursor cells

(2014) Daniel Veigel et al.   INTERNATIONAL JOURNAL OF CANCER

SLUG: Critical regulator of epithelial cell identity in breast development and cancer

(2014) Sarah Phillips et al.   Cell Adhesion & Migration

Relapsed Triple-Negative Breast Cancer: Challenges and Treatment Strategies

(2013) Valentina Guarneri et al.   DRUGS

Fatty acid synthase causes drug resistance by inhibiting TNF-α and ceramide production

(2013) Hailan Liu et al.   JOURNAL OF LIPID RESEARCH

Targeting cancer stem cells to suppress acquired chemotherapy resistance

(2013) S J Vidal et al.   ONCOGENE

Inherent and Acquired Resistance to Paclitaxel in Hepatocellular Carcinoma: Molecular Events Involved

(2013) Avtar Singh Meena et al.   PLoS One

Doxorubicin-enriched, ALDHbr mouse breast cancer stem cells are treatable to oncolytic herpes simplex virus type 1

(2012) Xiufen Zhuang et al.   BMC CANCER

The fatty acid synthase inhibitor orlistat reduces experimental metastases and angiogenesis in B16-F10 melanomas

(2012) F Seguin et al.   BRITISH JOURNAL OF CANCER

Suppression of Acquired Docetaxel Resistance in Prostate Cancer through Depletion of Notch- and Hedgehog-Dependent Tumor-Initiating Cells

(2012) Josep Domingo-Domenech et al.   CANCER CELL

Cell Plasticity and Heterogeneity in Cancer

(2012) N. D. Marjanovic et al.   CLINICAL CHEMISTRY

A Detailed Mammosphere Assay Protocol for the Quantification of Breast Stem Cell Activity

(2012) Frances L. Shaw et al.   JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA

New Synthetic Inhibitors of Fatty Acid Synthase with Anticancer Activity

(2012) Carlos Turrado et al.   JOURNAL OF MEDICINAL CHEMISTRY

Cancer stem cells and epithelial–mesenchymal transition: Concepts and molecular links

(2012) Christina Scheel et al.   SEMINARS IN CANCER BIOLOGY

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Co-expression of fatty acid synthase and caveolin-1 in pancreatic ductal adenocarcinoma: Implications for tumor progression and clinical outcome

(2011) Agnieszka K. Witkiewicz et al.   CELL CYCLE

Novel anti-fatty acid synthase compounds with anti-cancer activity in HER2+ breast cancer

(2010) G. Oliveras et al.   Annals of the New York Academy of Sciences

Resveratrol suppresses growth of cancer stem-like cells by inhibiting fatty acid synthase

(2010) Puspa R. Pandey et al.   BREAST CANCER RESEARCH AND TREATMENT

De novo Lipogenesis Protects Cancer Cells from Free Radicals and Chemotherapeutics by Promoting Membrane Lipid Saturation

(2010) E. Rysman et al.   CANCER RESEARCH

Deconstructing the molecular portraits of breast cancer

(2010) Aleix Prat et al.   Molecular Oncology

Doxorubicin in Combination with a Small TGFβ Inhibitor: A Potential Novel Therapy for Metastatic Breast Cancer in Mouse Models

(2010) Abhik Bandyopadhyay et al.   PLoS One

Breast Cancer Stem-Like Cells Are Inhibited by a Non-Toxic Aryl Hydrocarbon Receptor Agonist

(2010) Gérald J. Prud'homme et al.   PLoS One

Biology, Metastatic Patterns, and Treatment of Patients with Triple-Negative Breast Cancer

(2009) Carey K. Anders et al.   Clinical Breast Cancer

Association of Breast Cancer Stem Cells Identified by Aldehyde Dehydrogenase 1 Expression with Resistance to Sequential Paclitaxel and Epirubicin-Based Chemotherapy for Breast Cancers

(2009) T. Tanei et al.   CLINICAL CANCER RESEARCH

Sintasa de ácidos grasos como nueva diana antitumoral

(2009) Teresa Puig et al.   MEDICINA CLINICA

Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features

(2009) C. J. Creighton et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells

(2008) Sendurai A. Mani et al.   CELL

A new mechanism of drug resistance in breast cancer cells: fatty acid synthase overexpression-mediated palmitate overproduction

(2008) H. Liu et al.   MOLECULAR CANCER THERAPEUTICS

Saturated Fatty Acids Modulate Cell Response to DNA Damage: Implication for Their Role in Tumorigenesis

(2008) Li Zeng et al.   PLoS One

Generation of Breast Cancer Stem Cells through Epithelial-Mesenchymal Transition

(2008) Anne-Pierre Morel et al.   PLoS One